DelveInsight’s “Achondroplasia Market Insights, Epidemiology, and Market Forecast-2036” report delivers an in-depth understanding of the Achondroplasia, historical and forecasted epidemiology as well as the Achondroplasia Market Trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover which therapies are expected to grab the Achondroplasia Market Share @ https://www.delveinsight.com/sample-request/achondroplasia-market

Key Takeaways from the Achondroplasia Market Report

• In May 2026, At the Pediatric Endocrine Society’s 2026 Annual Meeting, BioMarin presented new long-term data regarding Voxzogo (vosoritide) for children with achondroplasia. The findings focus on the treatment’s impact beyond just height, showing positive effects on arm span, bone health, and overall growth proportionality. Achondroplasia, the most common form of dwarfism, is characterized by impaired endochondral bone growth; the data presented suggests that Voxzogo helps normalize the growth plate activity over extended periods. Importantly, the results indicate that long-term therapy is well-tolerated and contributes to improved skeletal health without compromising bone mineral density. This comprehensive look at growth metrics reinforces Voxzogo’s role as a foundational therapy in pediatric endocrinology, providing families and clinicians with the evidence needed to support its use from an early age through the end of the growth period.
• In March 2026, RIBOMIC announced the summary report on the Phase II clinical trial of umedaptanib pegol (anti-FGF2 aptamer) in paediatric patients with achondroplasia.
• In March 2026, RIBOMIC submitted an IND application for a Phase III clinical trial in Japan to the Pharmaceuticals and Medical Devices Agency (PMDA), the regulatory authority, for umedaptanib pegol (antiFGF2 aptamer) in pediatric patients (ages 2 to 14) with achondroplasia.
• In February 2026, BridgeBio Pharma announced positive topline results from the global Phase III (PROPEL 3) study of oral infigratinib in children with achondroplasia, successfully meeting the primary endpoint of change in annualized height velocity (AHV) at Week 52 (p<0.0001).
• According to DelveInsight’s estimates, the total diagnosed prevalent cases of Achondroplasia in the 7MM were approximately 28,500 in 2025, with the US accounting for the highest share.
• Among the EU4, France accounted for the highest number of diagnosed prevalent cases of Achondroplasia, followed by Germany, whereas Spain accounted for the lowest number of cases in 2025.
• The observed slight male predominance and earlier onset of Achondroplasia highlight the importance of early diagnosis, timely clinical intervention, and continuous monitoring to manage complications effectively.
• The leading Achondroplasia Companies such as Ascendis Pharma, QED Therapeutics (BridgeBio), Novartis, Sanofi, RIBOMIC, and others.
• Promising Achondroplasia Pipeline Therapies such as VOXZOGO (vosoritide), Infigratinib, RBM-007, SAR-442501, Recombinant human growth hormone, Infigratinib, TransCon CNP, Infigratinib, vosoritide, BMN 111, and others.

Stay ahead in the Achondroplasia Therapeutics Market with DelveInsight’s Strategic Report @ Achondroplasia Market Outlook

Achondroplasia Epidemiology Segmentation in the 7MM

• Total Diagnosed Prevalent Cases of Achondroplasia
• Gender-specific Diagnosed Prevalent Cases of Achondroplasia
• Total Treated Cases of Achondroplasia

Download the report to understand which factors are driving Achondroplasia Epidemiology Trends @ Achondroplasia Prevalence

Achondroplasia Approved Therapies

• Navepegritide; TransCon CNP (YUVIWEL): Ascendis Pharma

YUVIWEL, developed by Ascendis Pharma, is a long-acting prodrug of C-type natriuretic peptide (CNP) designed to address the underlying cause of achondroplasia. It works by counteracting the overactive FGFR3 signaling pathway, which normally inhibits bone growth, thereby restoring balance in growth plate activity. Using TransCon technology, it provides sustained release of active CNP, enabling continuous stimulation of chondrocyte proliferation and differentiation, ultimately promoting more normalized endochondral bone growth.

• Vosoritide (VOXZOGO): BioMarin Pharmaceutical

VOXZOGO, developed by BioMarin Pharmaceutical, is a C-type natriuretic peptide (CNP) analog designed to address the underlying pathology of Achondroplasia. It works by binding to natriuretic peptide receptor-B (NPR-B) and inhibiting the overactive FGFR3 signaling pathway, which suppresses bone growth. This restores normal growth plate function by promoting chondrocyte proliferation and differentiation. Unlike long-acting prodrugs, vosoritide is a short-acting therapy requiring daily administration, providing transient CNP activity to support endochondral bone growth.

Achondroplasia Pipeline Analysis

• Infigratinib (BBP-831/BGJ398): QED Therapeutics (BridgeBio)/Novartis/Kyowa Kirin

Infigratinib, developed by QED Therapeutics in collaboration with Novartis and Kyowa Kirin, is an oral, selective FGFR1–3 tyrosine kinase inhibitor designed to target the underlying genetic driver of Achondroplasia. It works by directly inhibiting the overactive FGFR3 signaling pathway responsible for impaired bone growth, thereby restoring downstream signaling balance in growth plate chondrocytes. This targeted mechanism aims to normalize endochondral ossification and promote skeletal growth, offering a precision-based approach that addresses the root cause of the disorder.

• RBM-007 (umedaptanib pegol): RIBOMIC

RBM-007, developed by RIBOMIC, is a PEGylated anti-FGF2 aptamer designed to target fibroblast growth factor 2 (FGF2), a key regulator involved in abnormal bone growth signaling in Achondroplasia. By specifically binding to and inhibiting FGF2, RBM-007 aims to modulate downstream pathways associated with impaired chondrocyte proliferation and differentiation. This targeted mechanism is intended to restore more balanced endochondral bone growth while minimizing off-target effects through its high specificity and localized biological action.

To learn more about Achondroplasia treatment guidelines, visit @ Achondroplasia Treatment Market Landscape

Achondroplasia Market Outlook

The Achondroplasia market is undergoing a significant transformation, shifting from a historically supportive care–focused approach toward targeted, disease-modifying therapies that address the underlying FGFR3-driven pathology. The approval and uptake of CNP analogs such as VOXZOGO (vosoritide) have established the first wave of mechanism-based treatment, while next-generation agents like TransCon CNP (navepegritide) aim to improve convenience and sustained efficacy through prolonged exposure. Additionally, emerging therapies such as Infigratinib highlight a growing focus on directly modulating FGFR3 signaling, further diversifying the therapeutic landscape.

Achondroplasia Drugs Uptake

The uptake of therapies in achondroplasia is expected to vary across CNP analogs, emerging long-acting peptide therapies, and supportive management approaches. Recently approved and emerging targeted therapies such as VOXZOGO and YUVIWEL are anticipated to demonstrate gradual to moderate uptake, supported by their disease-modifying mechanisms targeting the underlying FGFR3 pathway, defined pediatric patient populations, and increasing physician awareness. Their adoption is likely to be driven by the lack of curative options, limitations of traditional supportive care, and the need to improve long-term growth outcomes and quality of life.

Scope of the Achondroplasia Market Report

• Study Period: 2020-2034
• Coverage: 7MM
• Achondroplasia Companies: Ascendis Pharma, QED Therapeutics (BridgeBio), Novartis, Sanofi, RIBOMIC, and others.
• Achondroplasia Therapies: VOXZOGO (vosoritide), Infigratinib, RBM-007, SAR-442501, Recombinant human growth hormone, Infigratinib, TransCon CNP, Infigratinib, vosoritide, BMN 111, and others
• Achondroplasia Therapeutic Assessment: Achondroplasia current marketed and Achondroplasia emerging therapies
• Achondroplasia Market Dynamics: Achondroplasia market drivers and Achondroplasia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Achondroplasia Unmet Needs, KOL’s views, Analyst’s views, Achondroplasia Market Access and Reimbursement

Discover more about Achondroplasia Drugs in development @ Achondroplasia Clinical Trials Assessment

Table of Contents

1. Key Insights
2. Report Introduction
3. Achondroplasia Market Overview
4. Methodology of Achondroplasia Epidemiology and Market
5. Executive Summary of Achondroplasia
6. Key Events
7. Disease Background and Overview of Achondroplasia
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Therapies
11. Emerging Therapies
12. Achondroplasia: Market Analysis
13. Key Opinion Leaders’ Views
14. SWOT Analysis
15. Unmet needs
16. Market Access and Reimbursement
17. Appendix
18. Report Methodology
19. DelveInsight Capabilities
20. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/achondroplasia-market